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Abstract
Background—Bronchopulmonary Dysplasia (BPD) is an orphan disease and advances in 
prevention and treatment are lacking. Clinical efficacy of systemic corticosteroid therapy to reduce 
the severity of lung disease and BPD is highly variable. Our objective was to assess whether 
candidate SNPs in corticosteroid metabolism and response genes are associated with short-term 
phenotypic response to systemic corticosteroids in infants at high risk for BPD.
Methods—Pharmacogenetic analysis of data from a large randomized controlled trial 
(TOLSURF) in infants treated with dexamethasone or hydrocortisone using multivariate linear 
regression. The primary outcome was change in Respiratory Severity Score (RSS, mean airway 
pressure × FiO2) at day 7 of corticosteroid treatment.
Results—rs7225082 in the intron of CRHR1 is significantly associated with the magnitude of 
decrease in RSS 7 days after starting treatment with systemic corticosteroid (meta-analysis 
p=2.8×10−4). Each T allele at rs7225082 is associated with a smaller absolute change in RSS at 
day 7, i.e. less response to systemic corticosteroids.
Conclusion—Genetic variability is associated with corticosteroid responsiveness with regard to 
respiratory status in preterm infants. Identification of genetic markers of corticosteroid 
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responsiveness may allow for therapeutic individualization, with the goal of optimizing the risk to 
benefit ratio for an individual child.
Introduction
Bronchopulmonary dysplasia (BPD) is the most frequent complication of extreme 
prematurity. With increasing survival of the most immature infants, rates of BPD are 
increasing. Among a large cohort of infants less than 1500 grams at birth, the incidence of 
BPD increased between 2009 and 2012, up to 55% in infants born at 26 weeks and 40% in 
infants born at 27 weeks(1). Preventive therapies for BPD are limited, but postnatal 
treatment with systemic corticosteroids is a common practice grounded in studies that show 
improved pulmonary outcomes (2, 3). Corticosteroid treatment is highly variable among 
centers(4), in part due to concern regarding historic associations of high dose 
dexamethasone with central nervous system injury(5-7). In order for corticosteroid use to be 
optimized, the risk to benefit ratio must be improved such that a given infant is more likely 
to be benefited than harmed. Precision therapeutics is a burgeoning field that utilizes genetic 
information to individualize therapy, and this approach can be used to investigate target 
populations for optimal corticosteroid benefit. A long-term goal of pharmacogenetic studies 
in BPD is to preemptively delineate likely responders and non-responders and treat 
accordingly, and to delineate the biology of differential drug response.
In the original Trial of Surfactant Treatment (TOLSURF) study, many infants received 
systemic corticosteroids to decrease severity of lung disease and facilitate weaning from 
mechanical ventilation. In both dexamethasone- and hydrocortisone-treated infants, there is 
a known large range in phenotypic response to corticosteroid treatment. Many factors can 
contribute to this variability, including severity of lung disease, variation among centers in 
management of respiratory support and individual patient co-morbidities such as infections, 
etc. Genetic variation may also be an important and understudied contributor to differential 
corticosteroid response.
Genetic variation contributes to the risk of BPD (8, 9). Although yet unstudied in the BPD 
population, there is a high probability that genetic variability also contributes to variability 
in drug response. Variant alleles can influence drug metabolism, disposition and drug target 
sensitivity, and explain some of the heterogeneity in efficacy and toxicity that is observed 
within a patient population. A recent study (10) links neonatal genetic variation to 
respiratory phenotype at birth after maternal treatment with antenatal corticosteroids. In 
asthma, multiple single nucleotide polymorphisms (SNPs) in corticosteroid metabolism and 
response genes modify clinical response to inhaled corticosteroids(11-17). Though asthma 
and BPD are separate clinical entities, significant overlap occurs in their pathophysiology 
(inflammation, pulmonary architecture remodeling, bronchospasm, air trapping). Genes 
which are implicated in prenatal corticosteroid response and asthma corticosteroid response 
are potentially relevant to clinical corticosteroid response for BPD.
Given this background, our objective was to identify pharmacogenetic variants from 
pediatric asthma and perinatal corticosteroid treatment literature, and test these genes and 
variants for an association with clinical response to systemic corticosteroids in infants at 
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high risk for BPD. Our hypothesis states that variants associated with corticosteroid 
metabolism and response will correlate with short-term improvement in respiratory 
phenotype among a clinically homogenous cohort of preterm infants.
Methods
Our investigation was a secondary analysis of existing data collected during a large multi-
center, randomized, controlled trial of late surfactant therapy (TOLSURF study)(18, 19). 
The parent clinical trial was IRB-approved and parental consent was obtained, including 
collection and study of biospecimens (tracheal aspirate, urine and DNA).The Children’s 
Mercy Hospital IRB deferred review of this secondary study as non-human subjects research 
(use of de-identified historical data). The source population from the TOLSURF study 
included preterm infants receiving inhaled nitric oxide, birth weight 701±164 g, and 
gestational age 25.2±1.2 weeks. There was no differences found in the primary outcome of 
survival without BPD at 36 weeks between surfactant-treated and placebo groups. Thus, the 
groups were combined for secondary analyses.
Study Cohort
511 infants enrolled in the TOLSURF study were screened for eligibility. 126 infants met the 
following criteria: received systemic dexamethasone (DEX) or hydrocortisone (HC) at 
greater than 14 days of life for a minimum of seven days of treatment and on invasive 
ventilation at corticosteroids start. These criteria were selected to exclude corticosteroid 
exposure for blood pressure support and brief courses to treat airway edema for extubation. 
Of these 126, 39 were excluded due to (1) no DNA collected/isolated or failed early sample 
quality control during genome-wide SNP genotyping (n=26), (2) genotype call rates < 95% 
(n=3), (3) sibling from a multiple gestation (n=10, only one sibling was included to account 
for genetic relatedness). Ten were excluded for no primary outcome data; these infants were 
extubated to low flow NC and mean airway pressure (MAP) was not measureable.
Use of systemic corticosteroids was not prescribed by the study protocol but guidelines for 
their use were established by trial investigators. Approximately 75% of the source 
population were treated with postnatal corticosteroids, for various indications, one being 
BPD. For corticosteroid treatment for BPD, guidelines for use included withholding 
treatment until at least 2 weeks of age and only for infants with respiratory severity scores 
(RSS, FIO2 × mean airway pressure) of ≥7. Biologically equivalent doses of either 
hydrocortisone (15 mg/kg over 9 days) or dexamethasone (0.89 mg/kg over 10 days), based 
on doses and durations used in prior clinical trials, were recommended per TOLSURF study 
guidelines (20). BPD at 36 and 40 weeks was defined in the original study with the 
following criteria: Infants discharged in room air before 36 weeks were designated “No 
BPD.” Infants requiring ventilatory support and any level of supplemental oxygen, or with 
an effective FiO2 >30% by nasal cannula, were diagnosed with BPD (“severe” BPD by the 
NIH workshop definition (21)). Infants receiving mechanical ventilation, NCPAP, or >4 L of 
nasal cannula flow in room air were designated “Yes BPD.” Infants at 36 weeks receiving 
≤0.3 effective FiO 2 at <2 L flow or on nasal flow <4 L with room air were evaluated for 
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their requirement for respiratory support, determined by an oxygen/flow reduction (room 
air) challenge test(22).
Corticosteroid Response Phenotyping
In order to measure short-term phenotypic response to systemic corticosteroids, the change 
in RSS was used as a phenotypic marker. In order to evaluate response to corticosteroids, we 
went back to original TOLSURF data and obtained Mean Airway Pressure (MAP) and FiO2 
to calculate RSS at each time point. Then, RSS values for the day were averaged for a 24 
hour period and recorded on day 0 (day before treatment), day 4 of treatment and day 7 of 
corticosteroid treatment. Mode of ventilation was not taken into account in the RSS 
calculation, but MAP is reliably recorded from conventional ventilators, high frequency 
ventilators and BiPAP/SiPAP and CPAP modes. Only one infant in the analysis cohort was 
weaned to HFNC and his average RSS corresponded to a MAP of 2 cm H2O. Absolute 
change in RSS at day 7 is the primary outcome because this is a clinically meaningful time 
point and allows time for genetic effects to be assessed with respect to drug response.
Genotyping and Imputation Methods
DNA was isolated from cells in tracheal aspirates using an AutoGeneprep 965 instrument 
(Autogen, Holliston, MA) as per the manufacturer’s recommended protocols. When protein 
contamination was evident, DNA was re-precipitated using 3 volumes of 100% ethanol and 
3M ammonium acetate at a 3:1 ratio after incubation at −80°C overnight. DNA was 
quantified by Nanodrop (Thermofisher Scientific, Inc., Waltman MA) and quality was 
assessed using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Genotyping was 
performed on the Affymetrix Axiom LAT1 array (WorldArray 4, >800,000 SNPs). SNPs 
were filtered based on call rates < 95%, and Hardy-Weinberg equilibrium p-values < 10−6 
using PLINK(23). Subjects were evaluated for call rates, consistency between genetic and 
reported sex, autosomal heterozygosity, and cryptic relatedness/genetic identity using 
IBD/IBS estimates in PLINK(23). In the case of multiples, one individual was selected at 
random to be included in the study.
Using the complete set of ~800,000 markers, genomic levels of African and European 
ancestry were evaluated using ADMIXTURE(24) assuming three ancestral populations 
(K=3). Individuals from the HapMap CEU and YRI were genotyped on the same array and 
included as reference populations for European and African ancestry, respectively. Windows 
were offset by a factor of 0.2, the cutoff for linkage was set to 0.1, and a constant 
recombination rate was set to 10−8 (bp)−1. Genome-wide SNP genotypes were further used 
to impute candidate variants in the phase 3 1000 Genomes populations using the Michigan 
Imputation Server (https://imputationserver.sph.umich.edu/index.html. Variants were then 
filtered for imputation quality scores > 0.3.
Candidate SNP Identification
Multiple PubMed queries using search terms “steroid, corticosteroid, pharmacogenetics, 
asthma, response” were performed. Of the papers that discussed pharmacogenetics of 
corticosteroids, we chose to only include statistically significant SNPs from papers with an 
objective and measurable phenotype (e.g. FEV1). Manuscripts reporting genetic associations 
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of prenatal corticosteroid response and neonatal respiratory outcomes were included. The 
references of pertinent review articles were also reviewed for candidate results.
Statistical Analysis
Continuous variables are presented as means (SDs). Genetic association testing was 
performed at individual candidate SNPs, and at a collection of pooled SNPs within 50 Kb of 
candidate genes. Infants of maternal self-reported African-American (AA) and Non-
Hispanic White (NHW) race/ethnicity were analyzed separately, then combined in a meta-
analysis using Fisher’s method. Genetic associations with respiratory phenotypic response 
were tested at candidate SNPs within each racial/ethnic group using linear regression in 
PLINK (23), adjusting for gestational age, sex, birth weight, multiple gestation, baseline 
RSS and African genetic ancestry (for infants of maternal AA race). Gene-based association 
testing was performed using VEGAS2 v.02 by combining p-values across genotyped 
variants within each candidate gene, and including those within 50 Kb of the transcription 
start/stop site. Demographic difference between ethnic groups were assessed using Fisher’s 
exact t-tests. Associations between change in RSS at day 7 and long-term diagnosis of BPD 
at 36 and 40 weeks were tested with univariate binomial logistic regression. Two post-hoc 
exploratory analyses were performed, one including infants with missing data at day 7 of 
treatment (those weaned to low flow nasal cannula), and one with a small for gestational age 
(SGA) variable instead of birthweight, as birthweight and gestational age are highly 
correlated. P-values less than 0.05 were considered statistically significant for these 
comparisons.
Results
Figure 1 depicts the selection of the final pharmacogenetic cohort. The final analysis cohort 
consisted of 34 AA and 36 NHW infants (Table 1), and the seven Hispanic White infants 
were excluded from the initial analysis due to lack of sufficient sample size and power for 
genetic conclusions in this ethnic sub-group. There was a wide phenotypic range in response 
to systemic corticosteroids (Figure 2). Because the hydrocortisone- and dexamethasone-
treated groups were similar in clinical characteristics and clinical response variability, they 
were combined. Of all Table 1 variables tested for an association with the primary outcome, 
only baseline RSS (day 0 before steroid treatment) was significant, so this was adjusted for 
in all subsequent analyses. Day 7 change in RSS was not predictive of BPD status at 36 or 
40 weeks gestational age (p-value 0.614 and 0.831 respectively), suggesting that the final 
diagnosis of BPD is multi-factorial and short-term response to steroids is one of many 
important contributors.
The list of candidate SNPs tested for an association with phenotypic response are provided 
in Supplemental Table S1. We examined 21 SNPs in the proximity of 10 genes for 
associations with the primary outcome. Analyses were run within a racial/ethnic group then 
combined in a meta-analysis to avoid confounding due to population structure, differences in 
the distribution of steroid response, and differences in environmental exposures. Because of 
the small number of Hispanic infants, we limited our primary analysis to the AA and NHW 
infants. For the primary outcome of absolute change in RSS at day 7, the entire cohort had 
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an average change of −3.07 with standard deviation of 2.76. Genetic associations between 
candidate SNPs and absolute change in RSS at Day 7 are listed in Table 2.
We identified a significant association between rs7225082 in the intron of CRHR1 and 
absolute change in RSS at Day 7 following Bonferroni correction for 36 tests (meta-analysis 
p=2.8×10−4). In both AA and NHW infants, the T allele at rs7225082 was associated with a 
smaller absolute change in RSS at day 7, i.e. lower response to systemic corticosteroids 
(AA: average decrease in absolute change in RSS=1.2, p=0.017; NHW: average decrease in 
absolute change in RSS =1.74, p=0.016; meta p-value=2.8×10−4) (Table 2, Figure 3a,b). 
Rs7225082 was also significantly associated with % change at Day 7 (meta p-
value=1.8×10−4), as displayed in Figure 4. Compared to the average change in RSS of −3.07 
for the entire cohort, the difference in absolute change in RSS between genetic groups of 
−1.2 and −1.74 are relatively large. The T allele was at a frequency of 36% in AA infants, 
and 64% in NHW infants, consistent with observations from African and European 
continental frequencies from the 1000 Genomes Project (Figure 3c). Results were similar 
when all infants were pooled, including the 10 Hispanic white infants (total N=87), and 
adjusted by genomic ancestry (Table 2).
In an exploratory analysis, we included the ten children who were originally excluded 
because they missed outcome data at day 7 of treatment (Figure 1). We presume that these 
children were all weaned to low flow NC because they had no Mean Airway Pressure 
recorded in the TOLSURF dataset. In order to analyze these children, we set the RSS at day 
7 to 0.5 for all ten infants, and repeated the regression analysis. The direction of effect of the 
T allele at rs7225082 was the same (p-values: AA 0.04; NHW 0.006). Since the T allele 
maintained its association with less corticosteroid response in a larger cohort including ten 
more extremely good responders, it adds further support that rs7225082 has some influence 
on variability in corticosteroid response. In the second exploratory analysis, we included a 
binary SGA variable instead of birthweight. The direction of effect for the T allele at 
rs7225082 was the same (p-values: AA 0.03; NHW 0.02).
Four infants displayed continued worsening of their lung disease despite systemic 
corticosteroids, and all were TT homozygotes at rs7225082. When these four outliers whose 
lung disease continued to worsen despite treatment with corticosteroids (increase in RSS > 
1) were excluded, the association with rs7225082 is in the same direction, but does not reach 
statistical significance. This suggests that the underlying trend is the same direction within 
infants showing either no change in RSS, or an improvement in RSS over time. The loss of 
significance could be from smaller sample size or a “pushing over” effect of these four 
infants, but our goal in this study was to assess the complete range of clinical response to 
corticosteroids, and this includes those infants who continue to get worse despite therapy. 
None of the other candidate SNP association tests met Bonferroni corrected significance 
levels.
A gene based analysis was performed for two sets of candidate genes, those associated with 
corticosteroid response in asthma (eight genes) and those associated with perinatal 
corticosteroid response (three genes) (Supplemental Table S1). Within each racial/ethnic 
group, none of the candidate genes were significantly associated with phenotypic response 
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to corticosteroids following Bonferroni correction for multiple comparisons (Table 3). 
However, genetic variation in T showed an association at p=0.02 in infants of maternal AA 
race/ethnicity, and variation in SERPINA6 showed an association at p=0.03 in infants of 
maternal self-reported NHW race/ethnicity.
Discussion
To our knowledge, this is the first study to assess pharmacogenetic influences on drug 
response in premature infants at high risk for BPD. We capitalized on published literature to 
formulate a list of candidate genes and SNPs, and used an existing dataset containing both 
phenotypic data and genetic data for this proof of principle analysis. Our study is an 
important first step in bringing concepts of precision therapeutics to a very heterogeneous 
and difficult to treat population of preterm infants with respiratory failure. It is of paramount 
importance to develop predictive biomarkers of drug response in order to spare predicted 
“non-responders” the unwarranted risk of systemic corticosteroid therapy. This is especially 
important for a medication such as dexamethasone which has the potential to significantly 
help a sub-set of infants with developing BPD. The risk to benefit ratio of systemic steroids 
varies with your risk of developing BPD (25), as both “exposures” can lead to brain injury. 
And while a calculator that estimates BPD risk (26) may be useful in determining which 
infants to treat, genetic markers of likely responders could strengthen patient selection for 
steroid treatment.
We identified SNP rs7225082 in CRHR1 as associated with corticosteroid responsiveness 
and we also present gene and SNP results that do not meet Bonferroni adjustment for 
significance. We present all of the results because we also hope that this paper is hypothesis 
generating, and that these genetic variations may become significant in larger prospective 
cohorts. Although the effect size of SNP rs7225082 is small, the genetic variation in CRHR1 
may be important because of the prevalence of this variant. All ethnic populations have a 
relatively large proportion of individuals carrying the T allele at rs7225082 (Figure 3c), 
potentially contributing to partial or non-response to systemic corticosteroid treatment.
The most significant genetic association was between rs7225082 in the intron of CRHR1 
and absolute change in RSS at day 7, whereby individuals that carried the T allele had a 
smaller improvement in RSS scores. This was true for infants of both maternal Black/AA 
and NHW race, and given our study design we indeed had the most power to identify genetic 
associations that are shared among the two racial/ethnic groups. Interestingly, while the 
variant is common in both African and European populations, the allele associated with 
greater improvements in RSS scores is at higher frequency in populations with African 
ancestry. Genotypes were imputed at this variant and passed quality thresholds (Rsq=0.89). 
However, another variant in CRHR1 that was directly genotyped and in linkage 
disequilibrium with the imputed variant at R-squared=0.70 showed a similar trend 
(rs242941, p=5.9×10−3). This suggests our results are not driven by errors in genotype 
imputation, and strengthens our findings that genetic variation in CRHR1 contributes to drug 
response.
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The difference in absolute change of RSS between the genetic groups must be interpreted 
within a clinical context. Absolute change in RSS is not a variable commonly used in 
clinical practice, so ventilator settings which correspond to this genetic difference are 
provided as an example of the clinical significance. If an infant starts on a MAP of 11 and 
FiO2 of 0.5, the baseline RSS is 5.5. An infant with the GG genotype at rs7225082 would 
have on average a decrease in RSS of 3.1 in response to systemic steroids, corresponding to, 
for example, a decrease in MAP to 8 and FiO2 to 0.3, a clinically significant improvement in 
respiratory status. For each copy of the T allele, the change in RSS would likely be less. So a 
GT genotype infant might have a corresponding decrease in MAP to 10 and FiO2 to 0.4, an 
RSS of 4 and absolute change of 1.5, a less robust response. A TT genotype infant would 
respond even less. Depending on the size of the infant, this difference in steroid response 
may mean ability to wean from High Frequency Ventilation to conventional ventilation, or 
the decrease in overall toxic oxygen exposure to the developing lung. The variability in 
response to steroids is multi-factorial, and this SNP in CRHR1 explains a portion of this 
variability.
Corticotrophin releasing hormone receptor 1 (CRHR1) modulates inflammation through 
control of ACTH-induced cortisol production. SNPs in this gene may affect baseline 
endogenous corticosteroid levels and baseline airway inflammation, leading to variation in 
response to exogenous administration of systemic corticosteroids. The importance of genetic 
variation in CRHR1 to corticosteroid response has been described in Chronic Obstructive 
Pulmonary Disease (COPD)(27) asthma(12) and persistent pulmonary hypertension of the 
newborn(28). Genetic variation in the ligand for CRHR1, corticotropin releasing hormone 
(CRH), is associated with neonatal respiratory response to maternal prenatal corticosteroid 
therapy (10). Fetuses who carry the risk allele at rs7225082 are more likely to require CPAP/
ventilator postnatally (poor response to maternal corticosteroids) and correspondingly in our 
study, preterm infants who carry the risk allele have a poorer response to postnatal 
corticosteroids. Given the importance of this gene in other patient populations, the biologic 
plausibility, and the same directionality of effect in two patient populations, we feel 
confident that genetic variation in CRHR1 is important for corticosteroid response in 
premature infants.
In the gene based analysis, we identified two genes associated with absolute change in RSS 
at day 7 at p<0.05 that warrant additional investigation – SERPINA6 that was previously 
implicated in perinatal corticosteroid response, and the T gene that was previously 
implicated in corticosteroid response in asthma. SERPINA6 encodes an alpha-globulin 
protein with corticosteroid-binding properties. This is the major transport protein for 
endogenous glucocorticoids and progestins in the blood of most vertebrates. SERPINA6 
transcript number and protein function could regulate systemic bioavailability of 
endogenous glucocorticoids, as the protein sequesters up to 80% of circulating cortisol in an 
inactive complex (29). Increased levels of SERPINA6, genetically determined, could reduce 
unbound and biologically active levels of cortisol and influence tissue response to treatment. 
It is biologically plausible that alterations in SERPINA6 expression could modulate response 
to corticosteroid therapy in BPD.
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The T gene encodes a mesodermal developmental transcription factor and contributes to 
regulation in lung development. Alterations in the T gene could alter the temporal pattern of 
lung development, and thus affect lung maturity and responsiveness to corticosteroids. The T 
gene is expressed in adult lung(30), but the abundance in neonatal lung is not known. The 
importance of the T gene in corticosteroid response among patients with asthma was first 
reported in a large GWAS study in which the significant two SNPs were found in a 
transcription factor located 50 kb downstream of the gene(11). The SNP rs6456042 
(intronic) is in tight linkage disequilibrium with three other SNPs with known functional 
implications: rs3099266 (promoter region), rs1134481 (3’ UTR) and rs2305089 
(nonsynomous within coding region). Thus, although the top SNP in AA infants in our study 
is not in a coding region, it is likely a marker of carriage of other tightly linked functionally 
significant genetic changes.
Use of respiratory severity score (RSS) as the phenotypic biomarker provided an objective 
measure of pulmonary dysfunction at baseline and served as an index of improvement. The 
RSS allows latitude among individual treating physician philosophy in choosing the 
perceived least harmful combination of oxygen and positive airway pressure to achieve the 
patient’s ventilation goals. The RSS has been validated as a close correlate of oxygenation 
index(31). In addition, RSS is used extensively in studies of preterm infants beyond the first 
week of life when paO2 is unavailable (32-35). RSS at day of life thirty is predictive of 
clinically important outcomes of preterm infants needing protracted ventilation (36). While 
the change in RSS may be exaggerated when an infant weans from High Frequency 
Ventilation to conventional ventilation because often this includes a drop in the mean airway 
pressure, we believe that this improved RSS represents a change in lung pathology which is 
still valid to measure using this phenotypic marker. Our cohort did not have sufficient size to 
analyze genetic associations among infants only treated with one modality of invasive 
ventilation.
Many placebo-controlled studies have documented a short term pulmonary response to 
corticosteroids using endpoints such as the respiratory acuity score (37) peak inspiratory 
pressure (PIP) and oxygen need (38-40). More recently, McEvoy et al (41) compared short 
term effects of lower dose dexamethasone and demonstrated improved lung mechanics at 3 
and 5 days. Our study adds to the published literature by assessing contributors to variability 
in clinical response to steroids, moving the field from a population-based approach towards 
a more personalized medicine approach.
Our study has some weaknesses including small sample size, and no PCR validation of the 
significant SNP in CRHR1. These are common weaknesses among secondary analysis 
studies which use data collected for alternative scientific purposes. We believe that the 
question of steroid pharmacogenetics in BPD is important enough that working within these 
initial limitations is worthwhile. Additionally, we lack a validation cohort for the 
pharmacogenetic finding. Because of the challenges in making and reproducing gene-
disease (or gene-drug response) conclusions in complex disease based on small sample 
sizes(42), the research team is collaborating in a multi-site consortium and prospectively 
enrolling preterm infants at risk for BPD who are being treated clinically with systemic 
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corticosteroids in order to recruit a larger patient cohort and further study steroid 
pharmacogenetics.
Overall our results implicate genetic variation in CRHR1 in modifying the acute respiratory 
response to systemic corticosteroids in preterm infants treated for prevention of BPD. 
Although the identified significant SNP is likely not directly causal, these results add to the 
body of knowledge that endogenous steroid homeostasis may contribute to variability in 
response to treatment with exogenous corticosteroids. Additional studies are required to 
validate these associations and to identify the mechanistic effects of SNPs in CRHR1 on 
corticosteroid response.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
Pharmacogenetic Analysis Cohort Identification
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Figure 2: Distribution of short-term phenotypic steroid response at Day 7.
Each bar represents an infant treated with systemic dexamethasone (black bars) or 
hydrocortisone (grey bars). Negative values indicate a decrease in the respiratory severity 
score (a more positive response to steroids). (a) absolute change in RSS at day 7 of 
treatment. (b) percent change in RSS at day 7.
Lewis et al. Page 14
Pediatr Res. Author manuscript; available in PMC 2019 May 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3: Change in Respiratory Severity Score.
Each line represents the change in RSS between the day before treatment and 7 days of 
treatment. (a) African American (b) Non-Hispanic White. (c) Frequency of alleles in 
continental populations from the 1000 Genomes Project.
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Figure 4: 
Boxplot of % change in respiratory severity score at day 7, stratified by genotype at 
rs7225082 (Number of individuals: 19 GG, 38 GT, and 18 GT).
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